In this article
FDA Approval of Pafolacianine for Ovarian Cancer Imaging
Jan 2022: Pafolacianine (Cytalux, On Target Laboratories, LLC), an optical imaging agent, has been licenced by the Food and Drug Administration for adult patients with ovarian cancer as an adjuvant for interoperative detection of malignant lesions. Pafolacianine is a fluorescent medication that works by targeting the folate receptor, which is overexpressed in ovarian cancer. It’s employed using a Near-Infrared (NIR) fluorescence imaging system that’s been cleared by the FDA for pafolacianine-specific use.
Clinical Trial Results and Efficacy in Lesion Detection
In a single-arm, multicenter, open-label research (NCT03180307), 178 women diagnosed with ovarian cancer or with a strong clinical suspicion of ovarian cancer who were planned to have primary surgical cytoreduction, interval debulking, or recurrent ovarian cancer surgery were evaluated for efficacy. Pafolacianine was given to all of the patients. In addition to standard of care evaluations such as pre-surgical imaging, intraoperative palpation, and normal light examination of lesions, 134 patients got fluorescent imaging evaluation. At least one evaluable ovarian cancer lesion detected with pafolacianine that was not observed by routine visual or tactile inspection was found in 36 (26.9%) of these individuals. In the detection of ovarian cancer lesions confirmed by central pathology, the patient-level false positive rate of pafolacianine using NIR fluorescent light was 20.2 percent (95 percent CI 13.7 percent , 28.0 percent ).
Nausea, vomiting, abdominal pain, flushing, dyspepsia, chest discomfort, pruritus, and hypersensitivity were the most prevalent adverse effects in patients (1%).
Pafolacianine is given intravenously over 60 minutes, 1 to 9 hours before surgery, at a dose of 0.025 mg/kg. Using folate, folic acid, or folate-containing supplements within 48 hours of receiving pafolacianine is not recommended.
View full prescribing information for Cytalux
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.